iBio Inc (IBIO)
2.11
+0.01
(+0.48%)
USD |
NYAM |
Jun 28, 16:00
2.10
-0.01
(-0.47%)
After-Hours: 20:00
iBio SG&A Expense (TTM): 11.84M for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 11.84M |
December 31, 2023 | 12.64M |
September 30, 2023 | 17.48M |
June 30, 2023 | 19.02M |
March 31, 2023 | 23.30M |
December 31, 2022 | 25.09M |
September 30, 2022 | 22.67M |
June 30, 2022 | 21.75M |
March 31, 2022 | 21.51M |
December 31, 2021 | 21.51M |
September 30, 2021 | 21.80M |
June 30, 2021 | 22.99M |
March 31, 2021 | 19.51M |
December 31, 2020 | 17.18M |
September 30, 2020 | 14.09M |
June 30, 2020 | 11.71M |
March 31, 2020 | 11.77M |
December 31, 2019 | 11.64M |
September 30, 2019 | 12.45M |
June 30, 2019 | 12.33M |
March 31, 2019 | 12.10M |
December 31, 2018 | 11.86M |
September 30, 2018 | 11.06M |
June 30, 2018 | 10.68M |
March 31, 2018 | 10.58M |
Date | Value |
---|---|
December 31, 2017 | 10.82M |
September 30, 2017 | 10.58M |
June 30, 2017 | 10.55M |
March 31, 2017 | 9.833M |
December 31, 2016 | 9.399M |
September 30, 2016 | 8.732M |
June 30, 2016 | 7.685M |
March 31, 2016 | 6.957M |
December 31, 2015 | 5.776M |
September 30, 2015 | 5.394M |
June 30, 2015 | 5.022M |
March 31, 2015 | 5.519M |
December 31, 2014 | 5.248M |
September 30, 2014 | 4.997M |
June 30, 2014 | 4.196M |
March 31, 2014 | 3.203M |
December 31, 2013 | 3.481M |
September 30, 2013 | 3.469M |
June 30, 2013 | 4.243M |
March 31, 2013 | 4.734M |
December 31, 2012 | 4.751M |
September 30, 2012 | 5.457M |
June 30, 2012 | 5.623M |
March 31, 2012 | 6.885M |
December 31, 2011 | 7.565M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
11.64M
Minimum
Dec 2019
25.09M
Maximum
Dec 2022
17.61M
Average
18.25M
Median
SG&A Expense (TTM) Benchmarks
Imunon Inc | 8.396M |
Ocugen Inc | 30.20M |
Avalo Therapeutics Inc | 10.79M |
Petros Pharmaceuticals Inc | 9.842M |
NovaBay Pharmaceuticals Inc | 12.53M |